TY - JOUR
T1 - Biomimetic and immunomodulatory therapeutics as an alternative to natural exosomes for vascular and cardiac applications
AU - Villarreal-Leal, Ramiro A.
AU - Cooke, John P.
AU - Corradetti, Bruna
N1 - Funding Information:
BC acknowledges support through S?r Cymru II scheme, funded by the European Union's Horizon 2020 Research and Innovation Program under the Marie Sk?odowska-Curie grant agreement no. 663830, the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF) and Houston Methodist Research Institute. RAV acknowledges CONACYT for his graduate research fellow stipend (859295) at Tecnologico de Monterrey. JPC receives support from the National Institutes of Health (R01HL148338, R01HL133254, R01HL149303, R01GM125632) and the Cancer Prevention Research Institute of Texas (CPRIT RP150611). This work was made possible in part by the generous support of the George And Angelina Kostas Research Center for Cardiovascular Medicine; as well as the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation.
Funding Information:
BC acknowledges support through Sêr Cymru II scheme, funded by the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement no. 663830 , the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF) and Houston Methodist Research Institute . RAV acknowledges CONACYT for his graduate research fellow stipend (859295) at Tecnologico de Monterrey. JPC receives support from the National Institutes of Health ( R01HL148338 , R01HL133254 , R01HL149303 , R01GM125632 ) and the Cancer Prevention Research Institute of Texas (CPRIT RP150611 ). This work was made possible in part by the generous support of the George And Angelina Kostas Research Center for Cardiovascular Medicine; as well as the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/7
Y1 - 2021/7
N2 - Inflammation is a central mechanism in cardiovascular diseases (CVD), where sustained oxidative stress and immune responses contribute to cardiac remodeling and impairment. Exosomes are extracellular vesicles released by cells to communicate with their surroundings and to modulate the tissue microenvironment. Recent evidence indicates their potential as cell-free immunomodulatory therapeutics for CVD, preventing cell death and fibrosis while inducing wound healing and angiogenesis. Biomimetic exosomes are semi-synthetic particles engineered using essential moieties present in natural exosomes (lipids, RNA, proteins) to reproduce their therapeutic effects while improving on scalability and standardization due to the ample range of moieties available to produce them. In this review, we provide an up-to-date description of the use of exosomes for CVD and offer our vision on the areas of opportunity for the development of biomimetic strategies. We also discuss the current limitations to overcome in the process towards their translation into clinic.
AB - Inflammation is a central mechanism in cardiovascular diseases (CVD), where sustained oxidative stress and immune responses contribute to cardiac remodeling and impairment. Exosomes are extracellular vesicles released by cells to communicate with their surroundings and to modulate the tissue microenvironment. Recent evidence indicates their potential as cell-free immunomodulatory therapeutics for CVD, preventing cell death and fibrosis while inducing wound healing and angiogenesis. Biomimetic exosomes are semi-synthetic particles engineered using essential moieties present in natural exosomes (lipids, RNA, proteins) to reproduce their therapeutic effects while improving on scalability and standardization due to the ample range of moieties available to produce them. In this review, we provide an up-to-date description of the use of exosomes for CVD and offer our vision on the areas of opportunity for the development of biomimetic strategies. We also discuss the current limitations to overcome in the process towards their translation into clinic.
KW - Biomimetic
KW - Cardiovascular disease
KW - Cell therapy
KW - Exosome
KW - Extracellular vesicle
KW - Immunomodulation
KW - Humans
KW - Immunomodulating Agents/chemistry
KW - Exosomes/chemistry
KW - Biomimetic Materials/chemistry
KW - Cardiovascular Diseases/drug therapy
KW - Fibrosis
KW - Cell Communication/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85105873732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105873732&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2021.102385
DO - 10.1016/j.nano.2021.102385
M3 - Review article
C2 - 33774130
AN - SCOPUS:85105873732
SN - 1549-9634
VL - 35
SP - 102385
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
M1 - 102385
ER -